Clinical Study of Wajaâ??al-Mafasil (Rheumatoid Arthritis) with Therapeutic Efficacy Evaluation of Unani Compound Formulation in its Management

Central Council for Research in Unani Medicine New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

研究概览

暂无简介。

•1.Patients irrespective of gender will be selected for the study.
•2.Patients in the age group of 18 to 65 years fulfilling the criteria of the New American College of Rheumatology-European League Against Rheumatism 2010 for the diagnosis of rheumatoid arthritis.
•3.Patients, who are ready to sign the informed consent, follow the protocol and willing to participate in the clinical study voluntarily.
•4.Patients with features of preclinical rheumatoid arthritis, established rheumatoid arthritis and presence of active disease will be included in the study.

•1.Patients below 18 years and above 65 years of age.
•2.Patients who fail to follow up.
•3.Patients who fail to give written consent.
•4.Women who are pregnant, planning pregnancy, or breast feeding.
•5.Patients having other types of arthritis.
•6.Patients with the history of any systemic illness like uncontrolled diabetes, malignant hypertension, cardiovascular diseases, severe blood disorders and impaired renal function or patient with any other severe chronic or acute disease interfering with attendance for therapy.

发起方

Central Council for Research in Unani Medicine New Delhi